1. Retention, safety and efficacy of off-label conventional treatments and biologics for chronic calcium pyrophosphate crystal inflammatory arthritis
- Author
-
Julien Damart, Georgios Filippou, Mariano Andrès, Edoardo Cipolletta, Silvia Sirotti, Davide Carboni, Emilio Filippucci, Pilar Diez, Abhishek Abhishek, Augustin Latourte, Hang-Korng Ea, Sébastien Ottaviani, Jean-Guillaume Letarouilly, Renaud Desbarbieux, Sahara Graf, Laurène Norberciak, Pascal Richette, and Tristan Pascart
- Subjects
Rheumatology ,Pharmacology (medical) - Abstract
Objectives Very little is known on the efficacy and safety of drugs for the management of chronic calcium pyrophosphate (CPP) crystal inflammatory arthritis. To describe the drugs used in the management of chronic CPP crystal inflammatory arthritis in expert European centres, and to examine treatment retention. Methods This was a retrospective cohort study. Charts from patients with a diagnosis of persistent inflammatory and/or recurrent acute CPP crystal arthritis were reviewed in 7 European centres. Baseline characteristics were collected, and visits at months 3, 6, 12 and 24 included an assessment of treatment response and safety. Results 194 treatments were initiated in 129 patients. Colchicine (was used first-line in n = 73/86), methotrexate (used first-line in n = 14/36), anakinra (n = 27) and tocilizumab (n = 25) were the most prescribed treatments, while long-term corticosteroids, hydroxychloroquine, canakinumab and sarilumab were used occasionally. The 24-months on-drug retention was higher for tocilizumab (40%) than anakinra (18.5%)(p< 0.05), while the difference between colchicine (29.1%) and methotrexate (44.4%) was not statistically significant (p= 0.10). Adverse events lead to 14.1% of colchicine discontinuations (100% of diarrhoea), 4.3% for methotrexate, 31.8% for anakinra and 20% for tocilizumab, all other discontinuations were related to insufficient response or losses to follow-up. Efficacy outcomes did not differ significantly between treatments throughout follow-up. Conclusion Daily colchicine is the first-line therapy used in chronic CPP crystal inflammatory arthritis, which is considered efficient in a third to half of cases. Second-line treatments include methotrexate and tocilizumab, which have higher retention than anakinra.
- Published
- 2023
- Full Text
- View/download PDF